Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by iRhythm Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: iRhythm Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001388658-26-000072
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue | 60,967 | 53,830 | 119,004 | 103,291 |
| Gross profit | 163,205 | 132,857 | 304,558 | 242,073 |
| Operating expenses: | ||||
| Research and development | 19,843 | 21,012 | 41,201 | 42,531 |
| Acquired in-process research and development | 299 | 1,698 | 595 | 1,994 |
| Selling, general and administrative | 131,655 | 126,376 | 267,539 | 246,333 |
| Litigation settlements | 13,950 | — | 13,950 | — |
| Impairment charges | — | 2,479 | — | 2,479 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is iRhythm Holdings, Inc.'s R&D?
- iRhythm Holdings, Inc. (IRTC) reported R&D of $19.84M in Q2 2026.
- How has iRhythm Holdings, Inc.'s R&D changed year-over-year?
- iRhythm Holdings, Inc.'s R&D decreased by 5.6% year-over-year, from $21.01M to $19.84M.
- What is the long-term trend for iRhythm Holdings, Inc.'s R&D?
- Over 4 years (2021 to 2025), iRhythm Holdings, Inc.'s R&D has grown at a 21.6% compound annual growth rate (CAGR), from $38.67M to $84.61M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about iRhythm Holdings, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude